PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AZN vs. CTLT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AZN and CTLT is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

AZN vs. CTLT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AstraZeneca PLC (AZN) and Catalent, Inc. (CTLT). The values are adjusted to include any dividend payments, if applicable.

-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%15.00%AugustSeptemberOctoberNovemberDecember2025
-15.34%
9.47%
AZN
CTLT

Key characteristics

Sharpe Ratio

AZN:

-0.16

CTLT:

2.58

Sortino Ratio

AZN:

-0.08

CTLT:

4.35

Omega Ratio

AZN:

0.99

CTLT:

1.66

Calmar Ratio

AZN:

-0.12

CTLT:

0.75

Martin Ratio

AZN:

-0.28

CTLT:

12.40

Ulcer Index

AZN:

12.02%

CTLT:

4.28%

Daily Std Dev

AZN:

20.79%

CTLT:

20.54%

Max Drawdown

AZN:

-48.94%

CTLT:

-77.62%

Current Drawdown

AZN:

-25.04%

CTLT:

-55.41%

Fundamentals

Market Cap

AZN:

$203.68B

CTLT:

$11.52B

EPS

AZN:

$2.08

CTLT:

-$2.28

PEG Ratio

AZN:

0.71

CTLT:

529.00

Total Revenue (TTM)

AZN:

$39.18B

CTLT:

$3.40B

Gross Profit (TTM)

AZN:

$31.70B

CTLT:

$794.00M

EBITDA (TTM)

AZN:

$12.79B

CTLT:

$451.00M

Returns By Period

Over the past 10 years, AZN has outperformed CTLT with an annualized return of 9.71%, while CTLT has yielded a comparatively lower 8.59% annualized return.


AZN

YTD

0.24%

1M

-0.83%

6M

-17.15%

1Y

-0.25%

5Y*

7.66%

10Y*

9.71%

CTLT

YTD

0.00%

1M

0.00%

6M

9.26%

1Y

28.45%

5Y*

0.86%

10Y*

8.59%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AZN vs. CTLT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AZN
The Risk-Adjusted Performance Rank of AZN is 3838
Overall Rank
The Sharpe Ratio Rank of AZN is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of AZN is 3232
Sortino Ratio Rank
The Omega Ratio Rank of AZN is 3232
Omega Ratio Rank
The Calmar Ratio Rank of AZN is 4141
Calmar Ratio Rank
The Martin Ratio Rank of AZN is 4343
Martin Ratio Rank

CTLT
The Risk-Adjusted Performance Rank of CTLT is 9292
Overall Rank
The Sharpe Ratio Rank of CTLT is 9797
Sharpe Ratio Rank
The Sortino Ratio Rank of CTLT is 9898
Sortino Ratio Rank
The Omega Ratio Rank of CTLT is 9898
Omega Ratio Rank
The Calmar Ratio Rank of CTLT is 7676
Calmar Ratio Rank
The Martin Ratio Rank of CTLT is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AZN vs. CTLT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Catalent, Inc. (CTLT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AZN, currently valued at -0.16, compared to the broader market-2.000.002.00-0.161.84
The chart of Sortino ratio for AZN, currently valued at -0.08, compared to the broader market-4.00-2.000.002.004.00-0.083.57
The chart of Omega ratio for AZN, currently valued at 0.99, compared to the broader market0.501.001.502.000.991.49
The chart of Calmar ratio for AZN, currently valued at -0.12, compared to the broader market0.002.004.006.00-0.120.44
The chart of Martin ratio for AZN, currently valued at -0.28, compared to the broader market-30.00-20.00-10.000.0010.0020.00-0.286.80
AZN
CTLT

The current AZN Sharpe Ratio is -0.16, which is lower than the CTLT Sharpe Ratio of 2.58. The chart below compares the historical Sharpe Ratios of AZN and CTLT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
-0.16
1.84
AZN
CTLT

Dividends

AZN vs. CTLT - Dividend Comparison

AZN's dividend yield for the trailing twelve months is around 2.26%, while CTLT has not paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
AZN
AstraZeneca PLC
2.26%2.27%2.15%2.14%2.40%2.80%2.81%3.61%3.95%5.01%4.06%3.98%
CTLT
Catalent, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

AZN vs. CTLT - Drawdown Comparison

The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum CTLT drawdown of -77.62%. Use the drawdown chart below to compare losses from any high point for AZN and CTLT. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-25.04%
-55.41%
AZN
CTLT

Volatility

AZN vs. CTLT - Volatility Comparison

AstraZeneca PLC (AZN) has a higher volatility of 5.69% compared to Catalent, Inc. (CTLT) at 0.65%. This indicates that AZN's price experiences larger fluctuations and is considered to be riskier than CTLT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%2.00%4.00%6.00%8.00%10.00%AugustSeptemberOctoberNovemberDecember2025
5.69%
0.65%
AZN
CTLT

Financials

AZN vs. CTLT - Financials Comparison

This section allows you to compare key financial metrics between AstraZeneca PLC and Catalent, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab